Author Archive

Drug Patent Expirations for Jun 18 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

<TD align=right–>
ADVERTISE
HERE
Who are the leading pharmaceutical patent challengers? A report on<br />
Paragraph IV challenges<!–/td>

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Simple flat-rate
database subscription plans

Ultimate
Plan
Premium Plan Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Contact





Drug Patent Expirations for Jun 18 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
EPZICOM Viiv Hlthcare abacavir
sulfate; lamivudine
5,034,394*PED Jun 18, 2012
TRIZIVIR Viiv Hlthcare abacavir
sulfate; lamivudine; zidovudine
5,034,394*PED Jun
18, 2012
ZIAGEN Viiv
Hlthcare
abacavir sulfate 5,034,394*PED Jun
18, 2012

*Drugs may be covered by multiple
patents or regulatory protections. See the DrugPatentWatch
database for complete details.







DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Continue reading

Drug Patent Expirations for Jun 8 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Journal of Commercial Biotechnology
ADVERTISE
HERE

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Simple flat-rate
database subscription plans

Ultimate
Plan
Premium Plan Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Contact





Drug Patent Expirations for Jun 8 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
MOXEZA Alcon Pharms
Ltd
moxifloxacin hydrochloride 4,990,517*PED Jun
8, 2012
VIGAMOX Alcon
Pharms Ltd
moxifloxacin hydrochloride 4,990,517*PED Jun
8, 2012

*Drugs may be covered by multiple
patents or regulatory protections. See the DrugPatentWatch
database for complete details.







DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.

Share this:


Continue reading

Drug Patent Expirations for Jun 12 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Pharmaceutical Industry Intelligence
ADVERTISE
HERE

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Simple flat-rate
database subscription plans

Ultimate
Plan
Premium Plan Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Contact





Drug Patent Expirations for Jun 12 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
LESCOL Novartis fluvastatin
sodium
5,356,896*PED Jun 12, 2012
LESCOL XL Novartis fluvastatin
sodium
5,356,896*PED Jun 12, 2012

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.







DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Continue reading

Drug Patent Expirations for Jun 10 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Journal of Commercial Biotechnology
ADVERTISE
HERE

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Simple flat-rate
database subscription plans

Ultimate
Plan
Premium Plan Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Contact





Drug Patent Expirations for Jun 10 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
IMITREX Glaxosmithkline sumatriptan 5,705,520*PED Jun
10, 2012

*Drugs may be covered by multiple
patents or regulatory protections. See the DrugPatentWatch
database for complete details.







DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Continue reading

Drug Patent Expirations for Jun 6 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Pharmaceutical Industry Intelligence
ADVERTISE
HERE

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Simple flat-rate
database subscription plans

Ultimate
Plan
Premium Plan Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Contact





Drug Patent Expirations for Jun 6 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
DILACOR XR Watson
Labs
diltiazem hydrochloride 5,422,123 Jun 6,
2012
REQUIP XL Smithkline
Beecham
ropinirole hydrochloride 5,422,123 Jun 6,
2012
SULAR Shionogi
Inc
nisoldipine 5,422,123 Jun 6, 2012
ZYFLO CR Cornerstone
Therap
zileuton 5,422,123 Jun 6, 2012

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.







DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Continue reading

Drug Patent Expirations for Jun 2 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Pharmaceutical Industry Intelligence
ADVERTISE
HERE

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Simple flat-rate
database subscription plans

Ultimate
Plan
Premium Plan Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Contact





Drug Patent Expirations for Jun 2 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
IONSYS Incline Therap fentanyl
hydrochloride
6,317,629 Jun 2, 2012

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.







DrugPatentWatch Fills Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Continue reading

Drug Patent Expirations for May 21 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

<TD align=right–>
ADVERTISE
HERE
Who are the leading pharmaceutical patent challengers? A report on<br />
Paragraph IV challenges<!–/td>

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Simple flat-rate
database subscription plans

Ultimate
Plan
Premium Plan Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Contact





Drug Patent Expirations for May 21 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
ACTONEL WITH CALCIUM
(COPACKAGED)
Warner Chilcott calcium carbonate; risedronate
sodium
6,096,342*PED May 21, 2012
IMODIUM MULTI-SYMPTOM
RELIEF
Mcneil loperamide hydrochloride; simethicone 5,716,641 May 21,
2012

*Drugs may be covered by multiple
patents or regulatory protections. See the DrugPatentWatch
database for complete details.







DrugPatentWatch Fills Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Continue reading

Drug Patent Expirations for May 15 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

<TD align=right–>
ADVERTISE
HERE
Who are the leading pharmaceutical patent challengers? A report on<br />
Paragraph IV challenges<!–/td>

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Simple flat-rate
database subscription plans

Ultimate
Plan
Premium Plan Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Contact





Drug Patent Expirations for May 15 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
COMBIVIR Viiv
Hlthcare
lamivudine; zidovudine 5,859,021 May 15,
2012

*Drugs may be covered by multiple
patents or regulatory protections. See the DrugPatentWatch
database for complete details.







DrugPatentWatch Fills Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Continue reading

Drug Patent Expirations for May 17 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Journal of Commercial Biotechnology
ADVERTISE
HERE

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Simple flat-rate
database subscription plans

Ultimate
Plan
Premium Plan Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Contact





Drug Patent Expirations for May 17 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
PLAVIX Sanofi Aventis
Us
clopidogrel bisulfate 4,847,265*PED May
17, 2012

*Drugs may be covered by multiple
patents or regulatory protections. See the DrugPatentWatch
database for complete details.







DrugPatentWatch Fills Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Continue reading

Drug Patent Expirations for May 22 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

<TD align=right–>
ADVERTISE
HERE
FDA Orange Book archives from 2005 to<br />
present<!–/td>

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Simple flat-rate
database subscription plans

Ultimate
Plan
Premium Plan Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Contact





Drug Patent Expirations for May 22 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
ACTONEL Warner
Chilcott
risedronate sodium 6,096,342*PED May
22, 2012
VIRAMUNE Boehringer
Ingelheim
nevirapine 5,366,972*PED May
22, 2012
VIRAMUNE
XR
Boehringer Ingelheim nevirapine 5,366,972*PED May
22, 2012

*Drugs may be covered by multiple
patents or regulatory protections. See the DrugPatentWatch
database for complete details.







DrugPatentWatch Fills Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Continue reading